SPP Now Open

Botanix’s recently announced Share Purchase Plan (SPP) to raise up to A$3 million is now open for eligible AU/NZ shareholders.

The SPP opens today, 9 November 2022 and will remain open until 8:00pm AEDT on Wednesday, 23 November 2022 (unless extended or withdrawn). 

As the SPP is only open for two weeks, eligible shareholders are encouraged to apply for new shares as soon as possible.

Click here to read today’s ASX release.

A$5 million strategic Placement + Share Purchase Plan

Botanix (ASX:BOT) has today lifted its trading halt, sharing news that it has secured a commitment of A$5.0million from a highly respected institutional investor, Antares Capital. The Company will also offer a limited Share Purchase Plan (SPP) for eligible AU and NZ shareholders to raise up to A$3 million.

Click here to read today’s ASX release.

Significant R&D Tax Incentive Refund

Botanix has today announced it has received a Research and Development (R&D) Tax Incentive Refund of A$3,669,439 for the 2021/2022 financial year.

Click here to read today’s ASX release.

Promotion of Dr Howie McKibbon to Chief Operating Officer

Botanix has announced the promotion of Dr Howie McKibbon to the role of Chief Operating Officer, from his current position as Chief Commercial Officer.

Howie has more than 20 years of leadership experience in the pharmaceutical industry. He has launched 15 products including 11 in dermatology, and managed over 30 dermatology products. Importantly too, he played a significant role in two of the world’s largest dermatology acquisitions with combined valuations of $7.8 billion. 

Howie’s role will be expanded to include responsibility for all commercial, manufacturing, medical affairs and regulatory activities. We believe the breadth and depth of his experience will be invaluable as the Company prepares for FDA mid-cycle review of our lead asset, Sfpironium Bromide in late Q1 2023.  

Click here to read today’s ASX release.

Research Report by Euroz Hartleys – 14 October 2022

Botanix is pleased to share a recent analyst report published by Euroz Hartleys following last week’s announcement of positive results from our BTX 1702 Phase 1b/2 clinical trial for rosacea. 

Analyst Seth Lizee noted:

“We believe the rosacea treatment universe is prime for disruption, with a gap in the market for drugs that can deliver similar efficacy without the side effects and limitations. 

“Overall, these results strengthen BOTs already valuable pipeline of products, led by its lead asset Sofpironium Bromide, which the company recently submitted a New Drug Application (NDA) for to the FDA (12 month review process).”

Read the full report.

Positive BTX 1702 Phase 1b/2 Clinical Study for Rosacea

Botanix has released positive data from its BTX1702 rosacea clinical study. 

The Phase 1b/2 randomised, double-blind vehicle-controlled study examined the effects Botanix’s CBD formulation BTX 1702 in adults with moderate to severe papulopustular rosacea over an 8-week treatment period. The study tested two different concentrations of BTX 1702 topical gel – 10% and 20% – alongside a control arm. 

Pleasingly, both the 10% and 20% doses showed clinically meaningful results, with the 10% concentration showing statistically significant reduction in inflammatory lesions – an FDA-designated endpoint for the study. A review of the photo evidence from the study also demonstrated visibly reduced redness in target patients. 

Both doses were found to be very safe and well tolerated when compared to the control gel. 

Botanix medical advisor, Dr Ira Lawrence commented:

“To achieve this level of inflammatory lesion reduction and improvement in both IGA and CEA within 8 weeks is very exciting, particularly with such an excellent safety profile.”

Rosacea affects more than 430 million people worldwide, and the market for treatments is expected to reach US$2.6 billion by 2025. 

Click here to read today’s ASX release

Botanix submits NDA for FDA approval of Sofpironium Bromide

Botanix has today announced the submission of a New Drug Application to the FDA for approval of Sofpironium Bromide for the treatment of severe primary axillary hyperhidrosis (excessive underarm sweating).

Phase 3 studies of Sofpironium Bromide showed very high statistical significance for the treatment of primary axillary hyperhidrosis. In the US alone, there are approximately 7.3 million people who suffer from this disorder, with more than half of them actively seeking treatment.

Botanix President and Executive Chair, Vince Ippolito, said:

“We are delighted with the achievement of this submission milestone, and are targeting FDA approval in the US for 4Q CY2023 (following the usual 12-month FDA assessment and review period) to enable the commencement of sales in the US market.”

Click here to view ASX release

Capital Raise Update

Botanix has announced it has now closed the first tranche of its anticipated $7.5 million placement to new and existing institutional and sophisticated investors.

The second tranche of the Placement is an issue of New Shares to Botanix directors, who have  committed to subscribe for a total of $0.5 million of New Shares, which is subject to shareholder approval.  

Click here to view ASX release

$7.5m Capital Raise

Botanix has today announced it has received strong commitments to raise $7.5m through a placement to Australian and international institutions and sophisticated investors.

Funds will support the development of the Company’s lead asset – Sofpironium Bromide (SB) – a novel dermatology asset with positive Phase 3 data to treat primary axillary hyperhidrosis, a medical condition which results in excessive underarm sweating.

This will include support for the FDA approval process and preparation for commercial launch. The New Drug Approval (NDA) filing with the FDA remains on track for submission this quarter with a 12-month review process.

Click here to view ASX release

Research Report by Euroz Hartleys – 17 August 2022

Botanix (ASX:BOT) is pleased to advise that leading adviser Euroz Hartleys has released an analysis outlining the strong market opportunities for our most recent asset acquisition, Sofpironium Bromide.

Within the report, analyst Seth Lizee commented:

“Sofpironium Bromide’s target patient population is estimated to be ~3.7 million people in the United States, equal to the estimated number of patients with severe axillary hyperhidrosis seeking treatment…Even modest market penetration can translate into significant revenues.”

Read the full report.